Refractive Trend of Stage 3 Retinopathy of Prematurity

Document Type

Article

Publication Date

11-19-2018

Publication Title

Journal of pediatric ophthalmology and strabismus

Keywords

Angiogenesis Inhibitors, Bevacizumab, Disease Progression, Female, Humans, Infant, Infant, Newborn, Intravitreal Injections, Male, Prognosis, Receptors, Vascular Endothelial Growth Factor, Refraction, Ocular, Refractive Errors, Retinopathy of Prematurity, Vitreoretinal Surgery

Abstract

PURPOSE: To analyze the yearly refractive trend in patients with stage 3 retinopathy of prematurity (ROP) over a 7-year time period.

METHODS: This was a retrospective review of 70 eyes of 35 patients with stage 3 ROP.

RESULTS: Of the 70 eyes, 46 received laser ablation and 24 did not. There was a similar distribution between zone II and zone III disease in both groups (P = .87). The average final refraction in the laser group was -0.83 diopters (D) in comparison to +1.61 D in the no laser group. The final refractive change was -3.55 D in the laser group and -0.25 D in the no laser group. A greater myopic shift was observed in the first 2 years of life than between years 2 and 7 in both groups.

CONCLUSIONS: Infants who underwent laser treatment for stage 3 ROP tended to have higher myopia than those with stage 3 ROP who did not require treatment. [J Pediatr Ophthalmol Strabismus. 2018;55(6):403-406.].

Medical Subject Headings

Angiogenesis Inhibitors; Bevacizumab; Disease Progression; Female; Humans; Infant; Infant, Newborn; Intravitreal Injections; Male; Prognosis; Receptors, Vascular Endothelial Growth Factor; Refraction, Ocular; Refractive Errors; Retinopathy of Prematurity; Vitreoretinal Surgery

PubMed ID

30452767

Volume

55

Issue

6

First Page

403

Last Page

406

Find It @ Sladen

Share

COinS